Jeffrey Nelson
Fortuna: 57 824 $ al 31/08/2026
Fortuna: 57 824 $ al 31/08/2026
Jeffrey Nelson is Chief Operating Officer at Milestone Pharmaceuticals, Inc. since 2020.
Formerly, Mr. Nelson was Vice President-Program Management at Oncotelic Therapeutics, Inc. from 2015 to 2017 and Head-Clinical Operations at Axsome Therapeutics, Inc. from 2014 to 2015.
Mr. Nelson completed an undergraduate degree at Brandeis University in 2003.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 02/02/2026 | 49.848 ( 0,04 % ) | 57 824 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Director de Operaciones | 01/06/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2017 |
| AXSOME THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. BiotechnologyHealth Technology Engages in developing novel small-molecule therapeutics to treat cancer and eye diseases | Health Technology |
Milestone Pharmaceuticals, Inc.
Milestone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cardiovascular medicines | Health Technology |
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures novel therapies for the management of central nervous system | Health Technology |
Brandeis University
Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.